clinical trial · NCT02242942
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche·phase3·completed·n = 445
Lymphocytic Leukemia, ChronicChlorambucilVenetoclaxObinutuzumab
brief summary
This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The time on study treatment was approximately one year and the follow-up period will be up to 9 years
started
Dec 31, 2014
primary completion
Aug 17, 2018
completion
Aug 27, 2025
last updated
Nov 6, 2025
official title
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol